| Home : BerGenBio Presents Key Results From PhII Programme With Selective AXL Inhibitor Bemcentinib at DNB's 9th Annual Nordic Healthcare Conference |
|
Dec 12
2018 |
BerGenBio Presents Key Results From PhII Programme With Selective AXL Inhibitor Bemcentinib at DNB's 9th Annual Nordic Healthcare Conference |
|
- Bemcentinib proof of concept clinical data as monotherapy and in combination confirms focus on lung cancer & leukaemia - AXL biomarker correlation supports bemcentinib's proposed MoA, potential for Companion Diagnostic - Significant milestones expected over next 12 months BERGEN,... |
|
|
|
| Source:https://www.prnewswire.com:443/news-releases/bergenbio-presents-key-results-from-phii-programme-with-selective-axl-inhibitor-bemcentinib-at-dnb-s-9th-annual-nordic-healthcare-conference-884107479.html |
| |
|
Related News
|
» The Art of Face-to-Face Networking in the Digital Era by Steven David Elliot and Nick Cioffi
» RecRight Video Interviews Now Live on SAP® App Center
|
